# Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer

> **NCT00546364** · PHASE2 · TERMINATED · sponsor: **R-Pharm** · enrollment: 62 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2
- **DRUG:** Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2
- **DRUG:** Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2

## Key facts

- **NCT ID:** NCT00546364
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 62 (ACTUAL)
- **Why stopped:** Slow Accrual
- **Last updated:** 2016-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00546364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00546364, "Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00546364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*